Cargando…
The Role of Immunotherapy in Pancreatic Cancer
Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600738/ https://www.ncbi.nlm.nih.gov/pubmed/36290818 http://dx.doi.org/10.3390/curroncol29100541 |
_version_ | 1784816917655060480 |
---|---|
author | Mukherji, Reetu Debnath, Dipanjan Hartley, Marion L. Noel, Marcus S. |
author_facet | Mukherji, Reetu Debnath, Dipanjan Hartley, Marion L. Noel, Marcus S. |
author_sort | Mukherji, Reetu |
collection | PubMed |
description | Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients. |
format | Online Article Text |
id | pubmed-9600738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96007382022-10-27 The Role of Immunotherapy in Pancreatic Cancer Mukherji, Reetu Debnath, Dipanjan Hartley, Marion L. Noel, Marcus S. Curr Oncol Review Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients. MDPI 2022-09-23 /pmc/articles/PMC9600738/ /pubmed/36290818 http://dx.doi.org/10.3390/curroncol29100541 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mukherji, Reetu Debnath, Dipanjan Hartley, Marion L. Noel, Marcus S. The Role of Immunotherapy in Pancreatic Cancer |
title | The Role of Immunotherapy in Pancreatic Cancer |
title_full | The Role of Immunotherapy in Pancreatic Cancer |
title_fullStr | The Role of Immunotherapy in Pancreatic Cancer |
title_full_unstemmed | The Role of Immunotherapy in Pancreatic Cancer |
title_short | The Role of Immunotherapy in Pancreatic Cancer |
title_sort | role of immunotherapy in pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600738/ https://www.ncbi.nlm.nih.gov/pubmed/36290818 http://dx.doi.org/10.3390/curroncol29100541 |
work_keys_str_mv | AT mukherjireetu theroleofimmunotherapyinpancreaticcancer AT debnathdipanjan theroleofimmunotherapyinpancreaticcancer AT hartleymarionl theroleofimmunotherapyinpancreaticcancer AT noelmarcuss theroleofimmunotherapyinpancreaticcancer AT mukherjireetu roleofimmunotherapyinpancreaticcancer AT debnathdipanjan roleofimmunotherapyinpancreaticcancer AT hartleymarionl roleofimmunotherapyinpancreaticcancer AT noelmarcuss roleofimmunotherapyinpancreaticcancer |